Upstream Bio (UPBS) to Present Phase 2 VALIANT Trial Results Today

Upstream Bio (UPBS) will present results from its Phase 2 VALIANT trial evaluating its monoclonal anti-IgE therapy in patients with severe asthma during a virtual meeting of the American Thoracic Society today, February 11, 2026. The trial enrolled 304 adults with severe asthma and measured trough anti-IgE levels and key respiratory endpoints. If results show clinically meaningful improvement, the company may seek regulatory approval in the first half of 2026.